Biodefense stockpiles are helping to curb the monkeypox outbreak, but the vaccines are based on old technology with significant side effects. Are other vaccines on the horizon?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox
npj Vaccines Open Access 06 June 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harrison, C. Monkeypox response relies on three vaccine suppliers. Nat Biotechnol 40, 1306–1307 (2022). https://doi.org/10.1038/s41587-022-01463-3
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-022-01463-3
